Who owns Enlivex Therapeutics Ltd?
- Ticker: ENLV
- CUSIP Number: m4130y106
Tip: Access positions for across all investors
Analyze quarterly positions in Enlivex Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Enlivex Therapeutics stock
Who bought or sold Enlivex Therapeutics Ltd this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Susquehanna International | 102k | $388k | 323% | Mar 2024 |
|
Citadel Advisors | 73k | $276k | 397% | Mar 2024 |
|
Morgan Stanley | 72k | $273k | 63% | Mar 2024 |
|
Simplex Trading | 18k | $69k | 100% | Mar 2024 |
|
Geode Capital Management | 10k | $40k | 0% | Mar 2024 |
|
Wells Fargo & Company | 10k | $38k | 0% | Mar 2024 |
|
Group One Trading | 7.2k | $27k | 100% | Mar 2024 |
|
Jpmorgan Chase & Co | 7.2k | $27k | 2917% | Mar 2024 |
|
UBS Group | 3.1k | $12k | -16% | Mar 2024 |
|
Steward Partners Investment Advisory | 3.0k | $11k | 0% | Mar 2024 |
|
Barclays | 1.0k | $4.0k | 0% | Mar 2024 |
|
Advisor Group Holdings | 400.00 | $1.5k | 0% | Mar 2024 |
|
Red Tortoise | 150.00 | $568.995000 | 0% | Mar 2024 |
|
Qube Research & Technologies | 1.00 | $4.000000 | 0% | Mar 2024 |
|
Who sold out of Enlivex Therapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Edmond De Rothschild Holding | Dec 2023 | 13k | $35k |
Susquehanna International Group | Sep 2023 | 12k | $20k |
Citigroup | Dec 2023 | 4.7k | $13k |
Bank of America Corporation | Dec 2023 | 266.00 | $717.987200 |
Advisory Services Network | Dec 2023 | 43.00 | $116.001100 |